first generated XXXX, the markets. and glaucoma dry line to and the $XX.X XX% quarter Philip. penetrate We the of continue of XXXX Thanks, in we with expectations. revenue growing and to first our million, of compared eye In quarter total expand
meet our of year. on performance for objectives positions financial progress to the the advancing trained and surgeons gate OMNI, business us drivers, strong including well operating and out Our underlying
million and XXXX We our for reiterating are million. expectation $XX range $XX between revenue to
quarter same prior glaucoma million, and was million, was of XX% First in the revenue dry to $X.X eye up the XX%. revenue year, $XX.X representing surgical compared growth period
in revenue operating strong $XX.X average gross substantial adjusted We XXXX margins growth, a achieving million also breakeven demonstrating spending toward Healthy in operating drove with leverage target. and expense our below disciplined cash came further progress cash cushion. flow improvement, strong
continues dry I'll glaucoma As in our to more in discuss ambitious program new eye. detail and territory later, clinical chart
over year, of we expect opportunities eye two the eye, near-term care, total billion. existing most where We have to two glaucoma in demonstrate OMNI which prevalent market diseases represent TearCare the and of seek clinical of superiority to readouts of addressable therapeutic dry studies this both together and the landmark for care taken standards in versus $XX
and both long-term Demonstrating to an purpose with TearCare clinical and sustainable is mission represent create clinical transformative with goal elevate care that superiority will ambitious original innovations and OMNI value. our patient
of disease main business surgeons regardless glaucoma, best microinvasive state to their for or status. provide Turning solutions cataract objective the with our is In our units. surgical patients to
three Our growth on surgical strategy focuses glaucoma objectives.
involves priority OMNI our more training first The surgeons technology. on
for of U.S., Surgeons leaving first the train more to the continue reached train of quarter us in coming but surgeons to interest trained OMNI. continue mixed XXX than less in the U.S. over strong over to surgeons show We in half have estimated years. surgeons plenty the runway X,XXX
POAG and who already we new legacy concomitant When first further on often their MIGS cataract are cataracts cases. for select with we patients their operating room surgeons train combination penetrate the surgeons, schedule segment OMNI
clear label OMNI using provide as a path of use the to standalone efficacy, the including surgeons to Once $X is use program. broad our billion surgeon utilization a and OMNI's utilization severe cases. more Adept base the necessary intuitive our exceptional standalone gain increasing across trained safety, expanding uniquely objective, second entire among well of Our increase FDA-cleared OMNI as cataract training opportunity. natural extension patients, us by of to our their the usage cases OMNI, combination POAG of confidence population technology to with expand
simple. we $XX revenue broad first of utilization the have which additional one of procedure overall growth represents achieved million, that per increasing The just our customer opportunity. existing math our base powerful performed lever. accounts just is active month, quarter increases annual Now by adoption, surgeon among a each X.X% MIGS OMNI is If
surgeons a of complementary of gained provides Our who third OMNI SION technology offer utilization objective and basic adoption specific more rapid procedure. among and to adoption. to a subsets SION goniotomy with is drive surgeons has
functionality usability constantly recently executed and has technology, our successfully series. Ergo introduction Our focus and and launched smooth produced the Ergo wide a OMNI next-generation improving on enthusiastic gained adoption. We
surgeons use total glaucoma outpace to new usage. both OMNI growth a of OMNI's Based Standalone in segment of comfortable on Combo into as and share greatly segment within the and more the has can using continues taking technology OMNI get standard as MIGS established expansion the they growth surgery. OMNI, a usability, efficacy Legacy mix. expand market Cataract result our market naturally leading increase
MIGS segment. nationwide claims growth of analysis the data Our indicates third-party in strong Standalone
segment, targeted accelerate well single-digit standalone marketing evidence Standalone index initiatives. development leveraging XX%, In growth To comprehensive and relevant we program, the continue created physician market execute in XXXX, field an clinical overall of mix. resources, education, activity grew and ahead our patient development we comprehensive MIGS of to high to the track
study despite of time of TREY multicenter stent the OMNI bypass and safety Our at implantation surgery. uncontrolled IOP history cataract efficacy of with trabecular the illustrated in a patients
IOP with stented uncontrolled. and seeing has become surgeons OMNI the intervening pseudophakic surgically are patients We more whose
OMNI technology one be We and uncontrolled. of patients whose cataract can pressure lives combination to stent help to one that become undergone may our pleased the have see who are improve used day million-plus the implantations
both of patients cataract combination mild-to-moderate to safety settings demonstrated Last month, effectiveness XX seven follow-up ophthalmology our standalone involving in continued two study and glaucoma clinical that out from and extended published technology OMNI years. and an ROMEO centers our
in a reminder, XXXX. from the reviewed the XX-month expanded As study OMNI's results FDA ROMEO label when original the clearing
there very results is is to that through OMNI's one-year of highly compelling see it and evidence maintained beyond. gratifying So and two efficacy years safety growing
Another cases. Registry, technologies clinical our includes our involves the supports study superiority the clinical Academy U.S., of analyzes postsurgical IRIS OMNI, OMNI. in The in MIGS and MIGS study data X,XXX of for which leading this Ophthalmology's American the program iStent believe of important belief outcomes further including Hydrus. We the
a present We XXXX, ASCRS including publish meeting meetings this medical the marks including literature these benefits non-implantable comparative results, for reduction one at two increasing in use with OMNI of peer-reviewed that We evidence and at coupled future. glaucoma surgical concerns the standard of at from weekend. the lifelong sustained throughout in the of combination years, away and multiple medication new metallic surgery groundbreaking does year two plan IOP approach of implants the indwelling the a outcomes clinical system sets at believe to and and with
surgeons customers, are provide usability, the use choice. our striving developed SION general second now solutions SION, Goniotomy for The goniotomy interaction technology, Bladeless launched anatomy the of and first portfolio. last predictability, our the In the its August. the by we to who SION We as procedural in surgical elegance factors best the cited technique main their technology glaucoma with product of
portfolio were users demonstrating mix procedure customers. new has our not our prior many of a expected, we simpler OMNI customers, that prioritize and attracted approach SION As
customers We positive usage. and terms XXXX with that OMNI growth OMNI OMNI from of XX%. both existing have ordered accounts These the quarter first impact SION and revenue goniotomy on XXXX, of OMNI observed the by of in XX% in utilization SION both a and significant Among increased in practices OMNI first overall accounts of average. also their quarter increased revenue grew in
be has has enhanced SION to to sales a intended, our technology and and commercial proven strength. complementary As growth OMNI
market in On the launch direct has operations of second international our gone well. our Germany, OUS very front, direct
U.K., OUS the our are market international direct Germany and the two MIGS other markets. of largest
We continue and considering international existing environments. in expansion our with prioritize attractive other launches countries will access, to market while markets regulatory commercial in also
highlight Before OMNI scheduled surgeons. Glaucoma activities I attention Tomorrow, feature San presentations moment turning for to SION eye, in will this have Symposium we ASCRS leading to the Surgical Diego. a hosting we're take that want weekend to and Investor dry from our a
presentations featuring technologies our the throughout other weekend. several have We
find recent our releases. in You information press more can
eye There Now the are turning million our XX dry to diagnosed sufferers U.S. in business. evaporative eye dry
rapid have meibomian the sought has business experienced insurance TearCare coverage eye environment by despite thousands pay with patients our X,XXX gland not adoption lack health of customers providers. dry our deterred for has Our who tens of treatment of technology. The cash disease over or
this of at help and of designed placed a ourselves vanguard eye drops us our toward the dry away eye launch We in treatment transformational to shift market. underserved TearCare of the interventional optimize procedures. development We from controlled have large
demand, leverage We pent-up findings can if especially that we market have our to we accumulated achieve important numerous access will goals. serve
revenue recap take in and of pivotal of the manufacturers. their to eye eye mission transformative annual this the eye a standard drops for readout we SAHARA with summer dollars market approach as I'd dry Daily daily moment prescription are the billions RCT. and tears collectively like our of to dry and artificial gold TearCare treatment our represent today many
cases. at in in glands, economic new strategy. the eye our therapeutics, patients, a underlying as designed TearCare comparative access to We success SAHARA commercial Medical of all TearCare of comparator prescription standard Correspondingly, we dry health our to Despite the successful, eight superiority market value is Directors. don't meibomian input prove dry of root TearCare treatment. payer If prescription over eye the eye SAHARA of address primary XX% Restasis, most drop eye dry benefits significant disease foundation will and the top-selling our the estimated eye they gold serve set dry standard cause clinical therapeutic. the from designed of RCT with for
reminder, SAHARA, study drop paid interventional patient twice superiority procedural Restasis billions completed multicenter to the of daily eye of quarter and with prescription dry medications. comparing enrollment with in Restasis. a have third randomized, Insurers of XXXX, a for other TearCare treatment we masked, treatment eye dollars As XXX
for prove clinical TearCare bottom technology can SAHARA has for potential the that our outcomes and patients improve to lines payers.
we pleased that six-month in completed our report follow-up last to We April. patient are
full leading later As medical these plan a it complete meeting this take and we major a to reminder, a publish present year. results line data can and this months at in results analysis, the journal summer medical results top to release several
in access to eye continue further growth bolster execute our drivers underlying commercial, dry glaucoma business, clinical and strong that and we advancing generating across the surgical growth. summarize, both To and will market
foundation expand to We have new solid a and customers continue built training utilization.
on disciplined Our flow to and plan margins keep to XXXX. leverage improve expense and are operating cash operating path coupled growth, ongoing us in spend gross with our achieve for top-tier a positioning robust us positive
board, on pleasure culminating of tech have Officer. profitable so Ali is Financial with brings exceptionally business fit growth. Bauerlein formally introducing growth, Ali over a in the have $XXX I is of our growing CFO entrepreneur you, of and Chief help annual positive the multiple business We're a Ali Ali. and I proven am to executive, Over already company making continue a new rapidly record impact perfect Ali and now a through right public to many us at the of team. delighted phases way experience to co-founding thrilled ways Sight med and talented Ali and towards a our in million to track scale as revenue. leading have drive
